ERECTILE FUNCTION AS AT ADEQUATE QUALITY OF LIFE
- Authors: Pronkin E.A1
-
Affiliations:
- FSBEI HE RNSMU n.a. N.I. Pirogov of RMH
- Issue: No 3 (2017)
- Pages: 64-66
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289783
- ID: 289783
Cite item
Open Access
Access granted
Abstract
Erectile dysfunction (ED) is one of the most common problems in urology. Despite the fact that ED is not life-threatening condition, the appearance of sexual disorders leads to rapid personal and social maladjustment of the patient. Currently, European Association of Urology and American Urological Association recommend phosphodiesterase type 5 (PDE-5) inhibitors as first line therapy for patients with ED. Given the safety profile and the lack of convincing evidence of drug dependence, as well as the self-confidence of man against the backgeound of use of sildenafil (Dynamico), the drug can be considered as one of the leading drug in the treatment of ED. Chronic use of Dynamico by certain group of patients can be considered a way of maintaining a adequate quality of life.
Full Text
About the authors
E. A Pronkin
FSBEI HE RNSMU n.a. N.I. Pirogov of RMH
Email: dr.pronkin@gmail.com
PhD, Assistant Professor at the Department of Urology Moscow
References
- Johannes C.B., Araujo A.B., Feldman H.A., Derby C.A., Kleinman K.P., McKinlay J.B. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J. Urol. 2000;163:460-63.
- Ayta I.A., McKinlay J.B., Krane R.J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50-6.
- Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 1994;151(1):54-61.
- American Urology Association. Erectile Dysfunctions Guidelines Update Panel, June 2007. Chapter 1-10: AUA Guideline on the Management of Erectile Dysfunction: Diagnosis and Treatment Recommendations.
- Corona G., Mondaini N., Ungar A., Razzoli E., Rossi A., Fusco F. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J. Sex. Med. 2011;8(12):3418-32.
- Gresser U., Gleiter C.H. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil review of the literature. Eur. J. Med. Res. 2002;7:435-46.
- McMurray J.G., Feldman R.A., Auerbach S.M., Deriesthal H., Wilson N. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther. Clin. Risk Manag. 2007;3:975-81.
- Mulhall J., Althof S.E., Brock G.B., Goldstein I., Junemann K.-P., Kirby, M. Erectile Dysfunction: Monitoring Response to Treatment in Clinical Practice-Recommendations of an International Study Panel. J. Sex. Med. 2007;4:448-64.
- Giuliano F., Jackson G., Montorsi F., Martin-Morales A., Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int. J. Clin. Pract. 2010;64(2):240-55.
- Christiansen E., Guirguis W.R., Cox D., Osterloh I.H. Sildenafil Multicentre Study Group. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int. J. Impot. Res. 2000;12(3):177-82.
- El-Galley R., Rutland H., Talic R., Keane T., Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J. Urol. 2001;166(3):927-31.
- Montorsi F., Maga T., Strambi L.F., et al. Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. J. Urol. 2000;56(6):906-11.
- Vick R.N., Benevides M., Patel M., Parivar K., Linnet O., Carson C.C. The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. J. Urol. 2002;167(6):2618-23.
Supplementary files
